‘Skinny’ User-Fee Reauthorization Would Leave Out Diagnostics Reform
Executive Summary
A stripped-down version of the US FDA user-fee reauthorization package may be the best Congress can do before the August recess, but some say it won’t be enough.
You may also be interested in...
Diagnostics Reform Out As Congress Reaches Year-End Omnibus Compromise
A measure that would have moved diagnostics regulation under the US Food and Drug Administration has been culled from the year-end omnibus spending package.
Bipartisan Support For AdvaMed’s Legislative Priorities, Whitaker Says
AdvaMed’s Scott Whitaker and Michael Minogue outlined the trade group’s legislative goals for the rest of the year, chief among them regulatory oversight for lab-developed tests.
US Interim Funding Bill Gets President Biden’s Signature; Window Narrows For IVD Reg Reform
Passed by the US House and signed into law on 30 September, the Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023, avoids a partial government shutdown and furloughs in FDA user-fee programs including MDUFA. Policy riders stripped from the legislation, including for FDA oversight of lab-developed tests, could still find their way into a final FY 2023 spending omnibus.